Attacks on the biotech and pharmaceutical industry increased by 50% between 2019 and 2020, according to a BlueVoyant report. The report highlighted that nation-states are ramping up cyber-attacks on companies that are developing vaccines, and this is likely to increase as production and distribution gets underway. The analysis examined open-source records of 25 publicly reported attacks that have taken place in the last four years. It set out to define key risks and how COVID-19 has changed the threat landscape. Establishing that ransomware is still the number one threat vector for this industry, the report identifies the key risks that companies face and the steps they need to take to mitigate these.